SGLT-2is Mitigate Risk of Cardiovascular, Kidney Diseases in Patients with Type 2 Diabetes and AKD
Compared to nonusers, patients with type 2 diabetes and acute kidney disease administered SGLT-2is had a significantly lower risk of mortality, major adverse kidney events, and major adverse cardiovascular events.
Researchgate Heng Chih Pan Keelung Chang Gung Heng Chih Pan Chang Gung Research Database National Kidney Foundation Us Centers For Disease
Source: hcplive.com